Life sciences and healthcare Van Lanschot Kempen

Life Sciences & Healthcare

One-stop shop for European life sciences companies

Life sciences & healthcare

Established as the premier, pan-European, specialist investment bank in the life sciences & healthcare sector, Van Lanschot Kempen is a trusted adviser with many repeat clients. We are your one-stop shop with top-tier international expertise and a global investor network. Our Life Sciences & Healthcare team combines in-depth sector knowledge, scientific background and business experience. For corporate clients, our goal is to ensure that all M&A and ECM transaction processes run smoothly, while achieving the best results. For investors, we offer high-quality analysis of the broadest small/mid-cap European life sciences coverage, as well as trade execution and liquidity through our specialised marketing and trading services.

Unrivalled track record

Consistently successful results for our clients have led to high levels of repeat business, helping Van Lanschot Kempen build outstanding credentials over the years.

  • Leading pan-European bank for ECM transactions in the life sciences & healthcare sector

  • Outstanding stock-picking track record, consistently beating healthcare indices

  • Connecting EU life sciences companies with global institutional investors

  • Experts in block trades and providing liquidity

  • More than 175 successfully executed transactions, raising over €10 billion

  • Access to both European and US capital markets

Life Sciences Conference 1 - 3 April 2025

The Van Lanschot Kempen conference has become a central meeting place for global institutional investors and European Life Sciences companies. 
Read more

Transactions

Great cooperation makes for excellent transactions. Our outstanding sector knowledge combined with a strong focus on understanding stocks and companies ensures we have a superior industry network and distribution power, leading to a successful track record in the market. 

March 2025
maat-pharma-logo
Placement Agent
€13 million
PIPE
Right Arrow in Circle
March 2025
transaction logo image
Sole Financial Adviser
€185 million
Royalty financing agreement
Right Arrow in Circle
December 2024
io biotech
Sole Financial Adviser
€57.5 million
Venture debt financing
Right Arrow in Circle
March 2025
Pharming logo
Sole Financial Adviser
SEK 725 million
Recommended cash offer to acquire Abliva
Right Arrow in Circle
December 2024
transaction logo image
Financial Adviser to the Company
USD 479 million
US Public Offering
Right Arrow in Circle
December 2024
transaction logo image
Sole Financial Adviser
€20 million
Venture debt financing

Right Arrow in Circle
June 2024
zealand
Lead Manager
USD 1.0 billion
Accelerated Bookbuild Offering
Right Arrow in Circle
May 2024
merus
Lead Manager
USD 460 million
US Public Offering
Right Arrow in Circle
April 2024
Pharming logo
Sole Financial Adviser
New issue €100 million & repurchase €123 million
Convertible bond issue and repurchase
Right Arrow in Circle
February 2024
Autolus logo
Co-Manager
USD 350 million
US Offering
Right Arrow in Circle
January 2024
galapagos
Financial Adviser
€170 million
Sale of Jyseleca business to Alfasigma

Right Arrow in Circle
December 2023
zealand
Sole Financial Adviser
€90 million
Venture debt financing
Right Arrow in Circle
October 2023
Cantargia logo
Joint Global Coordinator                            & Joint Bookrunner
SEK 59.3 million
Directed Share Issue
Right Arrow in Circle
October 2023
transaction logo image
Joint Global Coordinator                        & Joint Lead Bookrunner
NOK 505 million
Accelerated Bookbuild Offering
Right Arrow in Circle
October 2023
synact pharma
Sole Financial Adviser
SEK 120 million
Structured Equity with Warrants
Right Arrow in Circle
August 2023
merus
Lead manager
USD 173 million
Capital Increase
Right Arrow in Circle
July 2023
argenx
Manager
USD 1.3 billion
Capital Increase
Right Arrow in Circle
June 2023
vicore pharma
Joint Bookrunner
SEK 500 million
Capital increase
Right Arrow in Circle
June 2023
transaction logo image
Financial Adviser
USD 182 million
Secondary sell-down
Right Arrow in Circle
May 2023
transaction logo image
Joint Global Coordinator & Joint Bookrunner
€25 million
Accelerated Bookbuild Offering
Right Arrow in Circle
April 2023
sequana medical
Joint Global Coordinator & Joint Bookrunner
€ 15.8 million
Accelerated Bookbuild Offering
Right Arrow in Circle
April 2023
zealand
Lead Manager
DKK 1.5 billion
Accelerated Bookbuild Offering
Right Arrow in Circle
March 2023
transaction logo image
Financial Advisor, Capital Markets Advisor & Placement Agent
USD 220 million
PIPE USD 91 million
Right Arrow in Circle
Feb 2023
curevac
Lead Manager
USD 250 million
US Public Offering
Right Arrow in Circle
Dec 2022
gensight
Sole Financial Adviser
€ 12.0 million
Convertible Note Issuance
Right Arrow in Circle
Dec 2022
hansa
Joint Global Coordinator & Joint Bookrunner
SEK 416 million
PIPE
Right Arrow in Circle
See all transactions

Coverage list

Curious to know more?

Jan de Kerpel Van Lanschot Kempen

Jan De Kerpel

Managing Director
Life Sciences and Healthcare
EmailMail Jan De Kerpel
Nadine Maalouf Van Lanschot Kempen

Nadine Maalouf

Managing Director
Life Sciences & Healthcare
EmailMail Nadine Maalouf

Suzanne van Voorthuizen

Head of Life Sciences Equity Research
Emails.vanvoorthuizen@vanlanschotkempen.com